Indianapolis-based Eli Lilly and Co. will team with German drugmaker Boehringer Ingelheim to develop diabetes treatments, as the U.S. pharmaceutical company pushes to fill a looming revenue gap created by expiring patents for several key drugs. Get the full story »
Inside these posts: Diabetes drug
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Avandia faces ban in Europe, severe limits in U.S.
European regulators said Thursday GlaxoSmithKline’s diabetes drug Avandia should be taken off the market but U.S. officials allowed it to stay, with major restrictions due to concerns about heart risks.
The differing rulings were an attempt to end a row over drug safety that has dogged the reputation of the medicine and its maker in recent years. Get the full story »
